David V. Erbe

2.0k total citations
25 papers, 1.3k citations indexed

About

David V. Erbe is a scholar working on Molecular Biology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David V. Erbe has authored 25 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 7 papers in Immunology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David V. Erbe's work include Amyloidosis: Diagnosis, Treatment, Outcomes (6 papers), Protein Tyrosine Phosphatases (5 papers) and Galectins and Cancer Biology (5 papers). David V. Erbe is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (6 papers), Protein Tyrosine Phosphatases (5 papers) and Galectins and Cancer Biology (5 papers). David V. Erbe collaborates with scholars based in United States, United Kingdom and Canada. David V. Erbe's co-authors include James F. Tobin, Mark Stahl, Yan Zhang, W.S. Somers, Lidia Mosyak, Jasbir Seehra, Shinji Ikemizu, Simon J. Davis, Suyue Wang and Kevin Fitzgerald and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Nature Biotechnology.

In The Last Decade

David V. Erbe

24 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David V. Erbe United States 15 674 430 240 185 123 25 1.3k
Hanibal Bohnenberger Germany 22 690 1.0× 287 0.7× 428 1.8× 163 0.9× 46 0.4× 86 1.6k
Susana Constantino Rosa Santos Portugal 17 664 1.0× 224 0.5× 464 1.9× 105 0.6× 127 1.0× 41 1.3k
Karl Welzenbach Switzerland 15 586 0.9× 636 1.5× 207 0.9× 68 0.4× 149 1.2× 18 1.7k
Anna Garuti Italy 21 644 1.0× 297 0.7× 477 2.0× 117 0.6× 59 0.5× 67 1.5k
Susanna Kiwala United States 7 882 1.3× 301 0.7× 241 1.0× 246 1.3× 84 0.7× 13 1.5k
Tetsuro Sano Japan 19 706 1.0× 216 0.5× 275 1.1× 221 1.2× 85 0.7× 49 1.4k
Ana L. Gomes United Kingdom 14 371 0.6× 239 0.6× 297 1.2× 125 0.7× 51 0.4× 23 1.1k
Patrícia A. Madureira Portugal 21 1.1k 1.7× 295 0.7× 293 1.2× 137 0.7× 46 0.4× 29 1.7k
Jon Lømo Norway 19 481 0.7× 266 0.6× 319 1.3× 213 1.2× 98 0.8× 38 1.1k
Muriel Busson France 23 727 1.1× 280 0.7× 468 1.9× 114 0.6× 140 1.1× 35 1.4k

Countries citing papers authored by David V. Erbe

Since Specialization
Citations

This map shows the geographic impact of David V. Erbe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David V. Erbe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David V. Erbe more than expected).

Fields of papers citing papers by David V. Erbe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David V. Erbe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David V. Erbe. The network helps show where David V. Erbe may publish in the future.

Co-authorship network of co-authors of David V. Erbe

This figure shows the co-authorship network connecting the top 25 collaborators of David V. Erbe. A scholar is included among the top collaborators of David V. Erbe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David V. Erbe. David V. Erbe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Polydefkis, Michael, Simina Ticau, David V. Erbe, et al.. (2021). Neurofilament Light Chain (NfL) as a Potential Biomarker of Treatment Response in Hereditary Transthyretin-Mediated Amyloidosis: Data from the Patisiran Global OLE Study (1291). Neurology. 96(15_supplement). 1 indexed citations
2.
Ticau, Simina, Gautham Sridharan, William Cantley, et al.. (2020). Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis. Neurology. 96(3). e412–e422. 72 indexed citations
3.
Ticau, Simina, Gautham Sridharan, William Cantley, et al.. (2020). Neurofilament Light Chain may Serve As a Biomarker of Neuropathy in Hattr Amyloidosis with Cardiomyopathy. Journal of Cardiac Failure. 26(10). S96–S96. 2 indexed citations
4.
Parker, Margaret M., Simina Ticau, James Butler, et al.. (2020). Transthyretin-stabilising mutation T119M is not associated with protection against vascular disease or death in the UK Biobank. Amyloid. 27(3). 184–190. 5 indexed citations
5.
Nioi, Paul, Simina Ticau, Gautham Sridharan, et al.. (2020). Neurofilament Light Chain (NfL) as a Potential Biomarker in Hereditary Transthyretin-Mediated (hATTR) Amyloidosis (771). Neurology. 94(15_supplement). 1 indexed citations
6.
Wood, Kyle D., Ross P. Holmes, David V. Erbe, et al.. (2019). Reduction in urinary oxalate excretion in mouse models of Primary Hyperoxaluria by RNA interference inhibition of liver lactate dehydrogenase activity. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1865(9). 2203–2209. 36 indexed citations
7.
Liebow, Abigail, Xingsheng Li, Timothy Racie, et al.. (2016). An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria. Journal of the American Society of Nephrology. 28(2). 494–503. 159 indexed citations
8.
Schmidt, Michael M., Sharon A. Townson, Amy Andreucci, et al.. (2013). Crystal Structure of an HSA/FcRn Complex Reveals Recycling by Competitive Mimicry of HSA Ligands at a pH-Dependent Hydrophobic Interface. Structure. 21(11). 1966–1978. 92 indexed citations
9.
Ivanciu, Lacramioara, Raffaella Toso, Paris Margaritis, et al.. (2011). A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia. Nature Biotechnology. 29(11). 1028–1033. 62 indexed citations
10.
Zhang, Yanling, Xiaotian Zhong, Yuanhong Li, et al.. (2008). H6PDH interacts directly with 11β-HSD1: Implications for determining the directionality of glucocorticoid catalysis. Archives of Biochemistry and Biophysics. 483(1). 45–54. 31 indexed citations
11.
Perreault, Mylène, David V. Erbe, & James F. Tobin. (2008). PPARδ Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities. PPAR Research. 2008(1). 125387–125387. 6 indexed citations
12.
Wan, Zhao‐Kui, Jinbo Lee, Rajeev Hotchandani, et al.. (2008). Structure‐Based Optimization of Protein Tyrosine Phosphatase‐1 B Inhibitors: Capturing Interactions with Arginine 24. ChemMedChem. 3(10). 1525–1529. 14 indexed citations
13.
Zhang, Yanling, May Tam, Zhao‐Kui Wan, et al.. (2007). An enzyme-linked immunosorbent assay to measure insulin receptor dephosphorylation by PTP1B. Analytical Biochemistry. 365(2). 174–184. 4 indexed citations
14.
Wan, Zhao‐Kui, Bruce Follows, Douglas Wilson, et al.. (2007). Probing acid replacements of thiophene PTP1B inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(10). 2913–2920. 35 indexed citations
15.
Wan, Zhao‐Kui, Jinbo Lee, Weixin Xu, et al.. (2006). Monocyclic thiophenes as protein tyrosine phosphatase 1B inhibitors: Capturing interactions with Asp48. Bioorganic & Medicinal Chemistry Letters. 16(18). 4941–4945. 49 indexed citations
16.
Erbe, David V., Yanling Zhang, Vipin Suri, et al.. (2006). Molecular activation of PPARγ by angiotensin II type 1-receptor antagonists. Vascular Pharmacology. 45(3). 154–162. 122 indexed citations
17.
Erbe, David V., Suyue Wang, Yanling Zhang, et al.. (2004). Ertiprotafib Improves Glycemic Control and Lowers Lipids via Multiple Mechanisms. Molecular Pharmacology. 67(1). 69–77. 75 indexed citations
18.
Erbe, David V., Suyue Wang, Yuzhe Xing, & James F. Tobin. (2002). Small Molecule Ligands Define a Binding Site on the Immune Regulatory Protein B7.1. Journal of Biological Chemistry. 277(9). 7363–7368. 41 indexed citations
19.
Zhang, Yan, James F. Tobin, David V. Erbe, et al.. (2001). Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature. 410(6828). 608–611. 380 indexed citations
20.
Fanger, Michael W. & David V. Erbe. (1992). Fcγ receptors in cancer and infectious disease. Immunologic Research. 11(3-4). 203–216. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hanibal Bohnenberger Breakdown of academic impact, for papers by Susana Constantino Rosa Santos Breakdown of academic impact, for papers by Karl Welzenbach Breakdown of academic impact, for papers by Anna Garuti Breakdown of academic impact, for papers by Susanna Kiwala Breakdown of academic impact, for papers by Tetsuro Sano Breakdown of academic impact, for papers by Ana L. Gomes Breakdown of academic impact, for papers by Patrícia A. Madureira Breakdown of academic impact, for papers by Jon Lømo Breakdown of academic impact, for papers by Muriel Busson
Rankless by CCL
2026